FDA, Alvotech and Teva Pharmaceuticals
Alvotech and Teva Pharmaceuticals announce FDA accepts Biologics License Application for AVT06
Alvotech and Teva Pharmaceuticals announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT06, Alvotech’s proposed biosimilar to Eylea (aflibercept) 2 mg.
The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...
Alvotech (ALVO) and Teva Pharmaceuticals (TEVA) announced that the FDA has accepted for review a Biologics License Application, or BLA, for ...
Axsome Therapeutics has resolved the patent infringement lawsuit that it filed against Teva Pharmaceutical Industries after the generics powerhouse sought FDA approval for a copycat to Axsome's ...
But as those fears abated, stocks revved higher, and by Thursday, all the major indices were near their MarketBeat Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now Teva ...
Shares of Catalyst Pharmaceuticals rose as the company reached a settlement agreement with Teva Pharmaceuticals related to Teva's plans for a generic version of Firdapse 10 mg tablets.
The transaction is expected to be completed by early 2016. Earlier this year, Teva bought Allergan Generics for a whopping $40.5 billion and made a failed $40 billion-dollar bid to buy Mylan ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback